Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT05421091 Completed - Clinical trials for Chronic Myeloid Leukemia

Special Drug Use-results Surveillance of Scemblix Tablets

Start date: July 4, 2022
Phase:
Study type: Observational

Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.

NCT ID: NCT05387330 Completed - Clinical trials for Chronic Myeloid Leukemia

Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment

Start date: April 1, 2018
Phase:
Study type: Observational

This study aims to monitor the levels of soluble L-selectin (sCD62L) and secreted protein acidic rich in cysteine (SPARC) in chronic phase chronic myeloid leukemia (CP-CML) patients at baseline and after three and six months of imatinib therapy and evaluated the effect of imatinib on their levels and correlated their levels to clinical and laboratory parameters.

NCT ID: NCT05286528 Completed - Clinical trials for Chronic Myeloid Leukaemia

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Start date: November 18, 2020
Phase:
Study type: Observational

The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary. The primary endpoint of this study is the overall survival of CML patients treated with tyrosine kinase inhibitors in Hungary. The Overall Survival (OS) of all enrolled patients, OS by sequence pattern and by the number of treatment lines will be analyzed. Secondary objectives are description of the treatment length in 1st and later lines, incidence and prevalence of CML, the patient demographics (as age, gender, comorbidities), average number of patients' comorbidities, most frequent comorbidities and patient number with comorbidities at baseline and at different treatment lines by investigated Thyrosine Kinase Inhibitor (TKI), distribution of the investigated TKI therapies by treatment lines

NCT ID: NCT05260203 Completed - Multiple Myeloma Clinical Trials

MargheRITA (Remote Intelligence for Therapeutic Adherence)

MargheRITA
Start date: June 4, 2022
Phase: N/A
Study type: Interventional

It is essential to improve clinical efficiency and management of hematological and oncological patients treated on an outpatient basis. The most promising operative way to achieve this result is the development of tele-oncology platforms, that allow not only a telemedicine visit, but also the patient support in the daily management of the disease and related disorders, as well as treatments and their complications. In this perspective, the RITA communication platform should be able to support the patient, the caregiver, the physician and the general practitioner in the management of the disease and its treatments.

NCT ID: NCT05218902 Completed - Clinical trials for Myelodysplastic Syndromes

A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

DIM Vidaza
Start date: February 25, 2022
Phase:
Study type: Observational

The purpose of this study is to assess the safety and effectiveness in the real-world setting among participants who are treated with Azacitidine in accordance with the China Product Label.

NCT ID: NCT05215639 Completed - Clinical trials for Acute Myeloid Leukemia

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets

VALOR
Start date: December 27, 2021
Phase:
Study type: Observational

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for intensive chemotherapy in Switzerland & Austria. Venetoclax is a drug approved to treat acute myeloid leukemia. All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive chemotherapy will be enrolled. Around 120 participants will be enrolled in the study in approximately 15 sites in Switzerland & Austria. Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 24 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 24 months.

NCT ID: NCT05209152 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Start date: November 14, 2022
Phase: Phase 1
Study type: Interventional

The main objective is to assess the safety, tolerability, and efficacy of AMG 176 as monotherapy and in combination with the 7-day regimen of azacitidine for the treatment of Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia (HR-MDS/CMML).

NCT ID: NCT05188326 Completed - Clinical trials for Acute Myeloid Leukemia

Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients

Start date: November 28, 2010
Phase: Phase 3
Study type: Interventional

The present study aims to compare the efficacy of postremission maintenance therapy with 5-Aza versus best supportive care (BSC) in a cohort of AML patients aged >60 years, who have achieved complete remission (CR) following conventional induction ('3+7') and consolidation chemotherapy.

NCT ID: NCT05166135 Completed - Clinical trials for Acute Myeloid Leukemia

Latin American Real-world Study in Acute Leukemia

LOYAL
Start date: December 10, 2021
Phase:
Study type: Observational

The objective of the study is to describe the current epidemiology, treatment patterns, outcomes and healthcare resource use of adult patients diagnosed with relapsed/refractory (R/R) B-cell ALL and de novo AML in 4 Latin American countries.

NCT ID: NCT05149339 Completed - Clinical trials for Acute Myeloid Leukemia

Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in Leukemia

Start date: March 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

A Disintegrin-like And Metalloprotease with Thrombospondin type 1 motif 13 (ADAMTS13) deficiency was incriminated in poor prognosis, high probability of serious complications and mortality in acute myeloid leukemia (AML) patients. Interleukin 6 (IL-6) produced from AML blasts decreases Cluster of differentiation 34 positive(CD34+) cells differentiation, and inhibits the ADAMTS13 actions. Vitamin D "as an Immune-modulator" inhibits the pro-inflammatory cytokines including IL-6. So, supplementation of vitamin D might help down regulation of interleukin-6 production. Aim of the study To evaluate the potential relation between Vitamin D status, ADAMTS13 and IL-6 in AML patients. Objectives 1. Assess Vitamin D level in AML patients 2. Assess ADAMTS13 and IL-6 in AML patients 3. Correlate between Vitamin D level and both of ADAMTS13 and IL-6